Blank Rome Represents Cancer Prevention Pharmaceuticals in Definitive Agreement and Planned Merger with Panbela Therapeutics
A Blank Rome deal team represented Cancer Prevention Pharmaceuticals, Inc. (“CPP”), in connection with its entry into a definitive agreement and plan of merger with Panbela Therapeutics Inc. (Nasdaq: PBLA) for a combination of Panbela Therapeutics stock and up to $60 million of future milestone and royalty payments. The transaction is expected to close by the second quarter of 2022.
CPP is a private clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases. The combined entity will have an expanded pipeline addressing an estimated aggregate five-billion-dollar market opportunity for the research/program areas of initial focus.
For more information, please read Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc. (press release, February 22, 2022).